Bristol Myers Squibb (NYSE:BMY) Posts Earnings Results, Beats Expectations By $0.25 EPS

Posted by Francis Steltz on Oct 31st, 2026

Bristol Myers Squibb (NYSE:BMY – Get Free Report) released its quarterly earnings results on Thursday. The biopharmaceutical company reported $1.35 EPS for the quarter, beating the consensus estimate of $1.10 by $0.25, FiscalAI reports. Bristol Myers Squibb had a net margin of 18.47% and a return on equity of 62.78%. The firm had revenue of $13.07 billion for the quarter, compared to analyst estimates of $12.72 billion. During the same quarter in the previous year, the company earned $1.63 EPS. The business’s revenue for the quarter was up 6.9% compared to the same quarter last year.

Here are the key takeaways from Bristol Myers Squibb’s conference call:

Strong third-quarter execution led to raised 2026 guidance. Revenue increased 7% to approximately $13.1 billion, growth-portfolio sales rose 12%, and non-GAAP EPS guidance is now $6.35–$6.55.
The growth portfolio is becoming increasingly diversified, with eight medicines each annualizing above $1 billion. Key contributors included BREYANZI, CAMZYOS, OPDUALAG, REVLIMID, and QVANTIG, whose sales grew 28% sequentially and are now annualizing above $1.3 billion.
BMS reported encouraging pipeline progress, including positive registrational results for Zenbexus, admilparant, RYZ101, and arlo-cel. The company also expects multiple additional readouts through 2027, including milvexian, SOTYKTU in lupus, Cobenfy, and golcadomide.
The company expects a significant $1.5 billion–$2 billion ELIQUIS revenue decline in 2027 as loss of exclusivity begins in Europe, while the broader legacy portfolio is expected to decline 3%–5% in 2026.
Management highlighted execution risks and ongoing uncertainty around several programs, including mixed dose results for admilparant, the need to improve Cobenfy patient starts and repeat prescribing, and a temporary clinical pause for autoimmune CAR-T candidate zola-cel following a fatal septic pneumonia case.

Bristol Myers Squibb Stock Up 1.7%

Shares of BMY traded up $1.07 during mid-day trading on Friday, hitting $62.46. 12,667,223 shares of the company’s stock were exchanged, compared to its average volume of 12,439,823. Bristol Myers Squibb has a fifty-two week low of $45.20 and a fifty-two week high of $68.64. The stock’s 50-day moving average is $62.80 and its 200-day moving average is $59.94. The company has a market cap of $127.59 billion, a price-to-earnings ratio of 13.85, a P/E/G ratio of 0.32 and a beta of 0.19. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.38 and a current ratio of 1.53.

Bristol Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 2nd. Shareholders of record on Friday, October 2nd will be paid a dividend of $0.63 per share. The ex-dividend date is Friday, October 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 4.0%. Bristol Myers Squibb’s dividend payout ratio is 55.88%.

Analysts Set New Price Targets

Several equities research analysts have issued reports on BMY shares. JPMorgan Chase & Co. raised their target price on Bristol Myers Squibb from $67.00 to $73.00 and gave the stock an “overweight” rating in a research note on Friday, July 31st. TD Cowen assumed coverage on Bristol Myers Squibb in a research note on Wednesday, August 5th. They issued a “buy” rating on the stock. Royal Bank Of Canada reiterated a “sector perform” rating on shares of Bristol Myers Squibb in a report on Monday, October 19th. The Goldman Sachs Group raised Bristol Myers Squibb from a “hold” rating to a “strong-buy” rating in a research report on Friday, October 16th. Finally, Argus upgraded shares of Bristol Myers Squibb from a “hold” rating to a “buy” rating and set a $75.00 price objective on the stock in a report on Wednesday, August 5th. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, sixteen have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Bristol Myers Squibb has a consensus rating of “Hold” and a consensus price target of $65.46.

View Our Latest Stock Report on BMY

Insider Activity

In related news, SVP Phil M. Holzer sold 500 shares of Bristol Myers Squibb stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total value of $33,750.00. Following the completion of the transaction, the senior vice president directly owned 16,862 shares in the company, valued at approximately $1,138,185. This trade represents a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.05% of the company’s stock.

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

Positive Sentiment: Bristol Myers Squibb reported third-quarter adjusted EPS of $1.35 and revenue of $13.07 billion, exceeding consensus estimates of $1.10 and $12.72 billion, respectively. Revenue increased 6.9% year over year. Bristol Myers Squibb Q3 revenue report
Positive Sentiment: The company raised its full-year 2026 revenue outlook to approximately $50 billion as its Growth Portfolio—including newer drugs—grew 12% to $7.7 billion, helping offset pressure from older products facing patent expirations. BMY Q3 earnings call highlights
Positive Sentiment: Barclays maintained its Buy rating, while management pointed to pipeline progress, cancer-trial data and increased use of artificial intelligence in drug research as potential longer-term catalysts. Barclays maintains Buy rating
Neutral Sentiment: The improved sales outlook is largely a revenue story: deal-related and higher in-process research and development charges contributed to a reduction in 2026 EPS guidance, and adjusted earnings fell from $1.63 a year earlier to $1.35. BMY earnings and guidance report
Negative Sentiment: Opdivo sales came in below expectations, highlighting launch execution risks and the continuing challenge of replacing revenue from aging blockbuster drugs. Bristol Myers Opdivo sales report
Negative Sentiment: Morgan Stanley cut its price target from $41 to $40 and reiterated an Underweight rating, implying substantial downside from the current trading level. Morgan Stanley BMY rating
Negative Sentiment: A separate analysis downgraded BMY, arguing that progress from newer medicines may not fully overcome the company’s upcoming patent cliffs. Bristol Myers patent-cliff analysis

Bristol Myers Squibb Company Profile

(Get Free Report)

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases. Its research and development activities span oncology, hematology, immunology, cardiovascular disease, neuroscience and other specialty areas.

The company’s portfolio includes oncology medicines such as Opdivo, Yervoy, Abraxane, Sprycel and Pomalyst, as well as Eliquis, an anticoagulant developed in partnership with Pfizer. Bristol Myers Squibb also markets immunology and neuroscience products, including Orencia and Sotyktu, and continues to invest in therapies based on biologics, cell therapy and other advanced treatment approaches.

Bristol Myers Squibb traces its roots to pharmaceutical businesses founded by Bristol-Myers in 1881 and E.R.

Earnings History for Bristol Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.